Squalene Epoxidase Metabolic Dependency Is a Targetable Vulnerability in Castration-Resistant Prostate Cancer

被引:28
|
作者
Xun Shangguan [1 ]
Ma, Zehua [2 ]
Yu, Minghao [1 ]
Ding, Jie [1 ]
Xue, Wei [2 ]
Qi, Jun [1 ]
机构
[1] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Urol, Sch Med, Shanghai 200092, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
关键词
CHOLESTEROL-SYNTHESIS; ANDROGEN RECEPTOR; MONOOXYGENASE; INHIBITION; MECHANISMS; PATHWAY; PTEN; PROGRESSION; THERAPIES; ENZYME;
D O I
10.1158/0008-5472.CAN-21-3822
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Considering the dismal prognosis of castration-resistant prostate cancer (CRPC), it is critical to identify novel therapeutic targets in this disease. Malignant cells have metabolic dependencies distinct from their healthy counterparts, resulting in therapeutic vulnerabilities. Although PTEN and TP53 are the most frequently comutated or codeleted driver genes in lethal CRPC, the metabolic dependencies underlying PTEN/p53 deficiency-driven CRPC for therapeutic intervention remain largely elusive. In this study, PTEN/p53 deficient tumors were determined to be reliant on cholesterol metabolism. Moreover, PTEN/p53 deficiency transcriptionally upregulated squalene epoxidase (SQLE) via activation of sterol regulatory element-binding protein 2 (SREBP2). In addition, PTEN deficiency enhanced the protein stability of SQLE by inhibiting the PI3K/Akt/GSK3 beta-mediated proteasomal pathway. Consequently, SQLE increased cholesterol biosynthesis to facilitate tumor cell growth and survival. Pharmacologic blockade of SQLE with FR194738 profoundly suppressed the invasive program of CRPC. Collectively, these results demonstrate a synergistic relationship between SQLE and PTEN/p53 deficiency in CRPC development and progression. Therefore, pharmacologic interventions targeting SQLE may hold promise for the treatment of patients with CRPC. Significance: This study reveals PTEN and p53 deficiency confers a dependence on SQLE-mediated cholesterol metabolism, providing insights for new therapeutic strategies for treating castration-resistant prostate cancer.
引用
收藏
页码:3032 / 3044
页数:13
相关论文
共 50 条
  • [31] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [32] Predicting the future in castration-resistant prostate cancer
    Verhagen, Paul
    LANCET ONCOLOGY, 2009, 10 (03): : 201 - 202
  • [33] Cabazitaxel for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sartor, Oliver
    FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
  • [34] Novel treatments for castration-resistant prostate cancer
    Sternberg, Cora N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S195 - S199
  • [35] Visceral Disease in Castration-resistant Prostate Cancer
    Pezaro, Carmel J.
    Omlin, Aurelius
    Lorente, David
    Rodrigues, Daniel Nava
    Ferraldeschi, Roberta
    Bianchini, Diletta
    Mukherji, Deborah
    Riisnaes, Ruth
    Altavilla, Amelia
    Crespo, Mateus
    Tunariu, Nina
    de Bono, Johann S.
    Attard, Gerhardt
    EUROPEAN UROLOGY, 2014, 65 (02) : 270 - 273
  • [36] Pathophysiology and therapy of castration-resistant prostate cancer
    Merseburger, A. S.
    Kuczyk, M. A.
    Wolff, J. M.
    UROLOGE, 2013, 52 (02): : 219 - 225
  • [37] Castration-resistant Prostate cancer: Treatment is differentiated
    Wolff, Johannes M.
    AKTUELLE UROLOGIE, 2011, 42 (02)
  • [38] Current State of Castration-Resistant Prostate Cancer
    Petrylak, Daniel P.
    AMERICAN JOURNAL OF MANAGED CARE, 2013, 19 (18): : S358 - S365
  • [39] Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
    Fizazi, Karim
    Shore, Neal
    Tammela, Teuvo L.
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (13): : 1235 - 1246
  • [40] Cabazitaxel for castration-resistant prostate cancer Reply
    de Bono, Johann Sebastian
    Sartor, Oliver
    LANCET, 2011, 377 (9760): : 122 - 123